A phase 1/2a, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
SparkCures ID | 1321 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 102 Patients |
Treatments |
|
Tags |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
INCLUSION CRITERIA
EXCLUSION CRITERIA
Please visit the ClinicalTrials.gov page for historical site information.
View CentersLearn more about how we work with trial sponsors